Anti-Infective & Vaccine Challenge Studies
The drive to develop new prophylactic vaccines has resulted from the increase in impact of emerging diseases, bioterrorism and resistance to existing antimicrobials, as well as the apparent increased virulence of some viruses, such as influenza. Charles River is working with companies that develop vaccines by providing in vivo challenge studies, in addition to a large portfolio of vaccine testing options.
Studies involve the deliberate infection of a healthy host, allowing for a greater understanding of the infecting pathogen and the potency/efficacy of a product. Many ethical and safety considerations need to be addressed for such studies, and assessment is dependent on the pathogen, route of administration and host species.
For those companies developing influenza vaccines, Charles River has added the capability to conduct short- and long-term influenza studies in ferrets and rodents under BSL-2 containment. Hemagglutination assay (HA), hemagglutination inhibition assay (HAI) and EID50 (embryo infectious dose) testing can also be conducted on samples generated during influenza studies.
- Various models available, including a vaginal candidiasis rat model
- Use of individually ventilated cages (IVCs)
- In-house microbiology department
- Characterization of challenge material
- Exploratory studies with the isolate
- Evaluation of candidate antigens for bacterial challenge studies
- Viral challenge studies and adjuvant selection testing
- Short- and long-term influenza studies in ferrets and rodents
- Medical Countermeasures (MCMs), including countermeasures for botulinum toxin in all seven serotypes
|기본 배송비||교환/반품 배송비|
결제 및 환불 안내
교환 및 반품 접수
|교환 및 반품 접수 기한|
|교환 및 반품 접수가 가능한 경우|
|교환 및 반품 접수가 불가능한 경우|
교환 및 반품 신청
Charles River의 다른 상품들
To ensure that client biopharmaceuticals, pharmaceuticals and medical devices are produced according to the strict requirements of Good Manufacturing Practice (GMP)
Protein, peptide, vector and plasmid products are particularly sensitive to environmental factors.
The drive to develop new prophylactic vaccines has resulted from the increase in impact of emerging diseases, bioterrorism and resistance to existing antimicrobials, as well as the apparent increased virulence of some viruses, such as influenza.
Potency determination is necessary for regulatory submission and lot release of all biopharmaceutical products
From preclinical lots through routine bulk harvest testing of clinical and marketed batches, contamination testing helps ensure the safety of your biologic before it is released for use in animals and humans. The characterization of the purification ...